

PUBLICATIONS

Please find below recent articles published by Hybrigenics related to the ubiquitin-proteasome system.

- Colombo M, Vallese S, Peretto I, Jacq X, Rain JC, Colland F, Guedat P. Synthesis and Biological Evaluation of 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile Analogues as Potential Inhibitors of Deubiquitinating Enzymes. **ChemMedChem** 2010 Feb 23.
- Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. **Biochem Soc Trans** 2010, 38:137-43.
- Cholay M., Reverdy C., Benarous R., Colland F., Daviet L. Functional interaction between the ubiquitin-specific protease 25 and the SYK tyrosine kinase. **Experimental Cell Research** 2010, 316(4):667-675.
- Colland F., Formstecher E., Jacq X., Reverdy C., Planquette C., Conrath S., Trouplin V., Bianchi J., Aushev V.N., Camonis J., Calabrese A., Borg-Capra C., Sippl W., Collura V., Boissy G., Rain J.C., Guedat P., Delansorne R., Daviet L. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. **Molecular Cancer Therapeutics** 2009, 8:2286-95.
- Zhu Y., Poyurovsky M.V., Li Y., Biderman L., Stahl J., Jacq X., Prives C. Ribosomal protein S7 is both a regulator and a substrate of MDM2. **Molecular Cell** 2009 14;35(3):316-26.
- Daviet L. and Colland F. Targeting Ubiquitin Specific Proteases for drug discovery. **Biochimie** 2008 90(2):270-83.

- Achour M., Jacq X., Rondé P., Alhosin M., Charlot C., Chataigneau T., Jeanblanc M., Macaluso M., Giordano A., Hughes A.D., Schini-Kerth V.B. and Bronner C.
The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. ***Oncogene* 2008 27(15):2187-97.**
- Guedat P. and Colland F.
Patented small molecule inhibitors in the ubiquitin-proteasome system. ***BMC Biochemistry* 2007 Nov 22;8 Suppl 1:S14.**
- Mousnier A., Kubat N., Massias-Simon A., Ségéral E., Rain J.C., Benarous R., Emiliani S. and Dargemont C.
von Hippel Lindau binding protein 1-mediated degradation of integrase affects HIV-1 gene expression at a postintegration step. ***Proc Natl Acad Sci.* 2007 104(34):13615-20.**
- Atfi A., Dumont E., Colland F., Bonnier D., L'Helgoualc'h A., Prunier C., Ferrand N., Clément B., Wewer U. and Theret N.
The disintegrin and metalloproteinase ADAM12 interact with the Transforming Growth Factor (TGF β) Type II Receptor and modulate TGF β signaling. ***Journal of Cell Biology* 2007 178(2): 201-8.**
- Formstecher E., Reverdy C., Cholay M., Planquette C., Trouplin V., Lehrmann H., Aresta S., Calabrese A., Arar K., Daviet L. and Colland F.
Combination of active and inactive siRNA impairs silencing efficiency in cancer cell lines. ***Oligonucleotides* 2006 16(4): 387-94.**
- Van der Horst A., de Vries-Smits A.M.M., Brenkman A.B., van Triest M.H., van den Broek N., Colland F., Maurice M.M. and Burgering B.M.T.
FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. ***Nature Cell Biology (Article)* 2006 Oct 8(10): 1064-73.**
- Colland F.
Cysteine Proteinases and their Inhibitors – Fifth International Conference, From Structure to Regulation and Biology, 2-6 September 2006. ***Iddb3 reports (RF690762).***
- Daviet L.
Targeting Ubiquitin for Drug Discovery and Development - Strategic Research Institute Conference, 26-27 June 2006. ***Iddb3 reports.***

-
- Colland F.

Ubiquitin and cancer: From Molecular Targets and Mechanisms to the Clinic - AACR conference, 18-22 January 2006. **IDrugs 2006 9(3)**.